The purpose of this study is to test the safety and effectiveness of the new study drug combination of Isatuximab, Pomalidomide, Elotuzumab, and Dexamethasone for the treatment of multiple myeloma. Researchers would like to study the possible side effects associated with this new study drug combination. They also want to see if the new study drug combination is better at treating multiple myeloma compared to other standard of care treatment options.
Isatuximab, Pomalidomide, Elotuzumab and Dexamethasone in Relapsed and/or Refractory MM
OPEN TO ACCRUAL